Ticker brief
VTVT
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
12
authors 14d
7
crowd 14d
+0.18
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-10-05 → 2026-10-12 · now +0.05 (−1 bearish … +1 bullish)
Who spoke7
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @OzmosiHealth | C | · | 3 | +0.07 |
| @PrismMarketView | C | · | 3 | +0.20 |
| @PrismDM | A | -2.76 | 2 | +0.23 |
| @BioStocks | C | -1.77 | 1 | +0.15 |
| @CrweWorld | C | · | 1 | +0.25 |
| @OpenOutcrier | C | · | 1 | +0.50 |
| @AlertsAndNews | C | -3.92 | 1 | +0.10 |
Recent signals12of 12 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-12 | @PrismMarketView | +0.05 | Summarizes company-sponsored survey data on hypoglycemia burden while noting it provides no new drug efficacy data. | · | tweet ↗ |
| 2026-10-11 | @AlertsAndNews | +0.10 | vTv Therapeutics announced a presentation on T1D burdens and its investigational oral adjunct therapy. | · | tweet ↗ |
| 2026-10-08 | @PrismDM | +0.30 | Reports FDA Orphan Drug Designation for an investigational sickle-cell candidate, while stressing it is not approval. | · | tweet ↗ |
| 2026-10-08 | @PrismMarketView | +0.35 | Reports FDA Orphan Drug Designation for an investigational sickle-cell therapy. | · | tweet ↗ |
| 2026-10-08 | @OpenOutcrier | +0.50 | FDA granted orphan-drug status to vTv Therapeutics' sickle-cell drug. | · | tweet ↗ |
| 2026-10-07 | @OzmosiHealth | +0.00 | Schedules Phase 3 cadisegliatin results for Q3 2027. | · | tweet ↗ |
| 2026-10-06 | @OzmosiHealth | +0.00 | vTv schedules Phase 3 cadisegliatin diabetes results for Q3 2027. | · | tweet ↗ |
| 2026-10-05 | @PrismDM | +0.15 | vTv completed enrollment of 166 patients in its Phase 3 CATT1 trial. | · | tweet ↗ |
| 2026-10-05 | @PrismMarketView | +0.20 | Reports completion of Phase 3 enrollment and expected mid-2027 topline timing. | · | tweet ↗ |
| 2026-10-05 | @OzmosiHealth | +0.20 | vTv Therapeutics completed enrollment in its Phase 3 CATT1 diabetes study. | · | tweet ↗ |
| 2026-10-05 | @CrweWorld | +0.25 | vTv Therapeutics completes enrollment in a Phase 3 diabetes study. | · | tweet ↗ |
| 2026-10-05 | @BioStocks | +0.15 | VTVT completed enrollment in its Phase 3 CATT1 study; topline data are due mid-2027. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.